{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T07:34:42Z","timestamp":1649057682321},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2017,6,5]],"date-time":"2017-06-05T00:00:00Z","timestamp":1496620800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Science and Technology Development Project of Jilin Province","award":["20150312033ZG"],"award-info":[{"award-number":["20150312033ZG"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1007\/s12282-017-0786-8","type":"journal-article","created":{"date-parts":[[2017,6,5]],"date-time":"2017-06-05T16:49:46Z","timestamp":1496681386000},"page":"790-793","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Secondary breast carcinoma after completely remitted chronic myeloid leukemia following targeted tyrosine kinase inhibitor therapy"],"prefix":"10.1007","volume":"24","author":[{"given":"Linlin","family":"Pan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junwu","family":"Duan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiqiang","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lirong","family":"Bi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Di","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhimin","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,6,5]]},"reference":[{"key":"786_CR1","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/ajh.24275","volume":"91","author":"E Jabbour","year":"2016","unstructured":"Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring. Am J Hematol. 2016;91:252\u201365.","journal-title":"Am J Hematol"},{"key":"786_CR2","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1586\/14737140.2016.1151356","volume":"16","author":"F Stagno","year":"2016","unstructured":"Stagno F, Stella S, Spitaleri A, et al. Imatinib mesylate in chronic myeloid leukemia: frontline treatment and long-term outcomes. Expert Rev Anticancer Ther. 2016;16:273\u20138.","journal-title":"Expert Rev Anticancer Ther"},{"key":"786_CR3","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1038\/leu.2016.20","volume":"30","author":"MB Miranda","year":"2016","unstructured":"Miranda MB, Lauseker M, Kraus MP, et al. Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV. Leukemia. 2016;30:1255\u201362.","journal-title":"Leukemia"},{"key":"786_CR4","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1038\/sj.leu.2403874","volume":"19","author":"L Roy","year":"2005","unstructured":"Roy L, Guilhot J, Martineau G, et al. Unexpected occurrence of second malignancies in patients treated with interferon followed by imatinib mesylate for chronic myelogenous leukemia. Leukemia. 2005;19:1689\u201392.","journal-title":"Leukemia"},{"key":"786_CR5","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.4103\/0973-1482.146095","volume":"10","author":"I Kaygusuz-Atagunduz","year":"2014","unstructured":"Kaygusuz-Atagunduz I, Toptas T, Yumuk F, et al. Newly diagnosed breast cancer in a patient receiving imatinib mesylate. J Cancer Res Ther. 2014;10:1107\u20138.","journal-title":"J Cancer Res Ther"},{"key":"786_CR6","first-page":"1183","volume":"34","author":"JC Hogue","year":"2014","unstructured":"Hogue JC, Morais L, Provencher L, et al. Characteristics associated with upgrading to invasiveness after surgery of a DCIS diagnosed using percutaneous biopsy. Anticancer Res. 2014;34:1183\u201391.","journal-title":"Anticancer Res"},{"key":"786_CR7","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/S0344-0338(11)80745-4","volume":"190","author":"S Luna-More","year":"1994","unstructured":"Luna-More S, Gonzalez B, Acedo C, et al. Invasive micropapillary carcinoma of the breast. A new special type of invasive mammary carcinoma. Pathol Res Pract. 1994;190:668\u201374.","journal-title":"Pathol Res Pract"},{"key":"786_CR8","first-page":"33","volume-title":"WHO classification of tumors. Pathology and genetics, tumors of the breast and female genital organs","author":"FA Tavassoli","year":"2003","unstructured":"Tavassoli FA, Devilee P. WHO classification of tumors. Pathology and genetics, tumors of the breast and female genital organs. Lyon: ARC Press; 2003. p. 33\u20136."},{"key":"786_CR9","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1038\/ncb1438","volume":"8","author":"NK Noren","year":"2006","unstructured":"Noren NK, Foos G, Hauser CA, et al. The EphB4 receptor suppresses breast cancer cell tumorigenicity through an Abl-Crk pathway. Nat Cell Biol. 2006;8:815\u201325.","journal-title":"Nat Cell Biol"},{"key":"786_CR10","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/387450a0","volume":"387","author":"L Brown","year":"1997","unstructured":"Brown L, McCarthy N. DNA repair. A sense-abl response? Nature. 1997;387:450\u20131.","journal-title":"Nature"},{"key":"786_CR11","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1634\/stemcells.2005-0069","volume":"23","author":"S Appel","year":"2005","unstructured":"Appel S, Balabanov S, Brummendorf TH, et al. Effects of imatinib on normal hematopoiesis and immune activation. Stem Cells. 2005;23:1082\u20138.","journal-title":"Stem Cells"},{"key":"786_CR12","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.breast.2010.01.020","volume":"19","author":"JI Yu","year":"2010","unstructured":"Yu JI, Choi DH, Park W, et al. Differences in prognostic factors and patterns of failure between invasive micropapillary carcinoma and invasive ductal carcinoma of the breast: matched case-control study. Breast. 2010;19:231\u20137.","journal-title":"Breast"}],"container-title":["Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12282-017-0786-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-017-0786-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-017-0786-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,10,19]],"date-time":"2017-10-19T19:34:25Z","timestamp":1508441665000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12282-017-0786-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,5]]},"references-count":12,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["786"],"URL":"https:\/\/doi.org\/10.1007\/s12282-017-0786-8","relation":{},"ISSN":["1340-6868","1880-4233"],"issn-type":[{"value":"1340-6868","type":"print"},{"value":"1880-4233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,5]]}}}